{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:36:09Z","timestamp":1794440169731,"version":"4.9.1"},"reference-count":121,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2025-25461991"],"award-info":[{"award-number":["RS-2025-25461991"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007334","name":"Ministry of Health and Family Welfare","doi-asserted-by":"publisher","award":["2710086729\/RS-2025-02172968"],"award-info":[{"award-number":["2710086729\/RS-2025-02172968"]}],"id":[{"id":"10.13039\/501100007334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"KHIDI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024-00397865"],"award-info":[{"award-number":["RS-2024-00397865"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025-02215541"],"award-info":[{"award-number":["RS-2025-02215541"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1053\/j.seminhematol.2025.12.004","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:45:29Z","timestamp":1766130329000},"page":"267-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape"],"prefix":"10.1053","volume":"62","author":[{"given":"Ebru","family":"Sezer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungyoun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junho","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2025.12.004_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101256","article-title":"Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma","volume":"70","author":"Yue","year":"2025","journal-title":"Blood Rev"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.12.004_bib0002","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"43","author":"Cho","year":"2016","journal-title":"Semin Oncol"},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2025.12.004_bib0003","article-title":"Multiple myeloma unpacked","volume":"43","author":"Gay","year":"2025","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0004","unstructured":"UniProt Consortium. BCMA \u2013 TNFRSF17 \u2013 Homo sapiens (Human). UniProt; 2025 [Accessed 7.11.25]: https:\/\/www.uniprot.org\/uniprotkb\/Q02223\/entry."},{"issue":"14","key":"10.1053\/j.seminhematol.2025.12.004_bib0005","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/cells14141077","article-title":"Resistance mechanisms to BCMA targeting bispecific antibodies and CAR Tcell therapies in multiple myeloma","volume":"14","author":"Tedder","year":"2025","journal-title":"Cells"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.004_bib0006","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CART cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther."},{"issue":"24","key":"10.1053\/j.seminhematol.2025.12.004_bib0007","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1158\/1078-0432.CCR-24-1872","article-title":"FDA approval summary: teclistamab A bispecific CD3 T cell engager for patients with relapsed or refractory multiple myeloma","volume":"30","author":"Baines","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0008","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-linvoseltamab-gcpt-relapsed-or-refractory-multiple-myeloma? [Accessed 09.09.25]."},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0009","unstructured":"GSK plc. Blenrep approved by US FDA for use in treatment of relapsed\/refractory multiple myeloma. London: GSK;2025 [Accessed 08.12.25]. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blenrep-approved-by-us-fda-for-use-in-treatment-of-relapsedrefractory-multiple-myeloma\/."},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0010","unstructured":"GSK plc. Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed\/refractory multiple myeloma. London: GSK; 2024 [Accessed 7.11.25]. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blenrep-belantamab-mafodotin-combinations-approved-in-eu-for-treatment-of-relapsedrefractory-multiple-myeloma\/."},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0011","unstructured":"ClinicalTrials.gov. Study of BCMA-CD3 T-cell engager in relapsed\/refractory multiple myeloma. Identifier: NCT04246047. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04246047. Accessed 09.02.25."},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.004_bib0012","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0013","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.004_bib0014","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.12.004_bib0015","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.12.004_bib0016","first-page":"1255","article-title":"Both APRIL- and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization","volume":"140","author":"Camvi\u00e9l","year":"2022","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.12.004_bib0017","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.3390\/ijms21155192","article-title":"B-cell maturation antigen (BCMA) as a target for new drug development in relapsed and\/or refractory multiple myeloma","volume":"21","author":"Abramson","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.12.004_bib0018","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.4049\/jimmunol.1900026","article-title":"Ancient BCMA-like genes herald B cell regulation in lampreys","volume":"203","author":"Das","year":"2019","journal-title":"J Immunol"},{"issue":"49","key":"10.1053\/j.seminhematol.2025.12.004_bib0019","first-page":"30663","article-title":"A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma","volume":"269","author":"Laabi","year":"1994","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.12.004_bib0020","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4049\/jimmunol.165.3.1322","article-title":"TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF)1, TRAF2, and TRAF3 and activates NF-\u03bab, Elk-1, c-jun N-terminal kinase, and p38 mitogen-activated protein kinase","volume":"165","author":"Hatzoglou","year":"2000","journal-title":"J Immunol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.12.004_bib0021","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1615\/CritRevImmunol.v32.i4.10","article-title":"Regulatory roles of the tumor necrosis factor receptor BCMA","volume":"32","author":"Coquery","year":"2012","journal-title":"Crit Rev Immunol"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0022","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3389\/fimmu.2018.02285","article-title":"BAFF and BAFF-receptor in B cell selection and survival","volume":"9","author":"Smulski","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.12.004_bib0023","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3109\/10428194.2013.862619","article-title":"B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidyl inositol 3-kinase pathway in lymphoma B cells","volume":"55","author":"Secreto","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0024","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.3389\/fimmu.2018.02969","article-title":"TRAF1 signaling in human health and disease","volume":"9","author":"Edilova","year":"2018","journal-title":"Front Immunol"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.12.004_bib0025","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/ni.1678","article-title":"Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-\u03bab signaling","volume":"9","author":"Vallabhapurapu","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0026","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3389\/fimmu.2018.02161","article-title":"TRAF3 as a multifaceted regulator of B lymphocyte survival and activation","volume":"9","author":"Bishop","year":"2018","journal-title":"Front Immunol"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0027","unstructured":"Elsevier. TRAF3 \u2013 an overview. ScienceDirect Topics; [Accessed 7.11.25]: https:\/\/www.sciencedirect.com\/topics\/immunology-and-microbiology\/traf3."},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0028","unstructured":"QIAGEN GmbH. B Cell Activating Factor Signaling. Hilden: GeneGlobe;[Accessed 7.11.25]: https:\/\/geneglobe.qiagen.com\/us\/knowledge\/pathways\/b-cell-activating-factor-signaling."},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2025.12.004_bib0029","doi-asserted-by":"crossref","first-page":"P102","DOI":"10.1186\/1742-4690-11-S1-P102","article-title":"TRAF5-mediated tax ubiquitination modulates IKK phosphorylation but not binding to NEMO","volume":"11","author":"Bonnet","year":"2014","journal-title":"Retrovirology"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.004_bib0030","first-page":"88","article-title":"B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages","volume":"20","author":"Jamroziak","year":"2022","journal-title":"J Transl Med"},{"issue":"16","key":"10.1053\/j.seminhematol.2025.12.004_bib0031","doi-asserted-by":"crossref","first-page":"9156","DOI":"10.1073\/pnas.160213497","article-title":"B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1","volume":"97","author":"Shu","year":"2000","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0032","unstructured":"National Center for Biotechnology Information. A proliferation-inducing ligand (APRIL \/TNFSF13). In: Madame Curie Bioscience Database. Austin (TX): Landes Bioscience; [Accessed 7.11.25]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK6132\/."},{"issue":"7","key":"10.1053\/j.seminhematol.2025.12.004_bib0033","first-page":"1494","article-title":"TRAF molecules in cell signaling and in human diseases","volume":"25","author":"Xie","year":"2013","journal-title":"Cell Signal"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.004_bib0034","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12964-024-01699-3","article-title":"Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy","volume":"22","author":"Wang","year":"2024","journal-title":"Cell Commun Signal"},{"issue":"26","key":"10.1053\/j.seminhematol.2025.12.004_bib0035","doi-asserted-by":"crossref","first-page":"6860","DOI":"10.1182\/blood-2011-03-342394","article-title":"Defining the role of TORC1 and TORC2 in multiple myeloma","volume":"118","author":"Maiso","year":"2011","journal-title":"Blood"},{"issue":"25","key":"10.1053\/j.seminhematol.2025.12.004_bib0036","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood."},{"issue":"4","key":"10.1053\/j.seminhematol.2025.12.004_bib0037","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.12.004_bib0038","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.12.004_bib0039","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/leu.2011.192","article-title":"MRK003, a \u03b3-secretase inhibitor, exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin\u2019s lymphoma","volume":"26","author":"Ramakrishnan","year":"2012","journal-title":"Leukemia"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.12.004_bib0040","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0041","unstructured":"National Center for Biotechnology Information (NCBI). TNFRSF13C (tumor necrosis factor receptor superfamily member 13C), Gene ID: 115650 [Homo sapiens]. Bethesda (MD): National Library of Medicine (US). [Accessed 7.11.25]. https:\/\/www.ncbi.nlm.nih.gov\/gene\/115650\/."},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0042","unstructured":"National Center for Biotechnology Information (NCBI). Homo sapiens TNFRSF13C transcript variant 1 (NM_052945.4), mRNA. Bethesda (MD): National Library of Medicine (US). [Accessed 9.12.25]. https:\/\/www.ncbi.nlm.nih.gov\/nuccore\/NM_052945.4."},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0043","unstructured":"UniProt Consortium. UniProtKB \u2013 Q96RJ3 (BAFF-R) [Homo sapiens]. Geneva (Switzerland): UniProt; [Accessed 9.12.25]. https:\/\/www.uniprot.org\/uniprotkb\/Q96RJ3\/entry."},{"issue":"5","key":"10.1053\/j.seminhematol.2025.12.004_bib0044","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","article-title":"BAFF, APRIL and their receptors: structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin Immunol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.12.004_bib0045","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/bi048227k","article-title":"Selectivity of BAFF\/BLyS and APRIL for binding to the TNF family receptors BAFFR\/BR3 and BCMA","volume":"44","author":"Day","year":"2005","journal-title":"Biochemistry"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.12.004_bib0046","first-page":"455","article-title":"BAFF-R specific activation of TRAF6 and the PI3K pathway in malignant B cells","volume":"38","author":"Secreto","year":"2014","journal-title":"Leuk Res"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.12.004_bib0047","article-title":"BAFF signalling in health and disease","volume":"1868","author":"Schweighoffer","year":"2021","journal-title":"Biochem Biophys Acta \u2013 Mol Cell Res."},{"issue":"3\u20134","key":"10.1053\/j.seminhematol.2025.12.004_bib0048","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cytogfr.2008.04.006","article-title":"an enigmatic BAFF\/APRIL receptor, with new unappreciated biochemical and biological properties","volume":"19","author":"Mackay","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0049","unstructured":"National Center for Biotechnology Information. TNFRSF13B (tumor necrosis factor receptor superfamily member 13B). Gene ID: 23495 [Homo sapiens]; [Accessed 7.11.25]. https:\/\/www.ncbi.nlm.nih.gov\/gene\/23495\/."},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0050","unstructured":"National Center for Biotechnology Information (NCBI). Homo sapiens TNFRSF13B (TACI) transcript variant 1 (NM_012452.3), mRNA. Bethesda (MD): National Library of Medicine (US). [Accessed 9.12.25]. https:\/\/www.ncbi.nlm.nih.gov\/nuccore\/NM_012452.3."},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0051","series-title":"Structural and functional analysis of the TNFRSF13B\/TACI receptor","author":"Sazzini","year":"2010"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.12.004_bib0052","doi-asserted-by":"crossref","first-page":"7218","DOI":"10.1074\/jbc.M411714200","article-title":"Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding","volume":"280","author":"Hymowitz","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0053","unstructured":"UniProt Consortium. UniProtKB \u2013 O14836 (TACI) [Homo sapiens]. Geneva (Switzerland): UniProt; [Accessed 7.11.25]. https:\/\/www.uniprot.org\/uniprotkb\/O14836\/entry."},{"issue":"8","key":"10.1053\/j.seminhematol.2025.12.004_bib0054","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/ni.1914","article-title":"The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88","volume":"11","author":"He","year":"2010","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.12.004_bib0055","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood-2007-09-110874","article-title":"TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts","volume":"111","author":"Bossen","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.004_bib0056","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1084\/jem.192.1.137","article-title":"TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation","volume":"192","author":"Xia","year":"2000","journal-title":"J Exp Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.12.004_bib0057","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jmb.2004.08.040","article-title":"The crystal structure of a proliferation-inducing ligand, APRIL","volume":"343","author":"Wallweber","year":"2004","journal-title":"J Mol Biol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.12.004_bib0058","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.12.004_bib0059","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.cdd.4401647","article-title":"Heparan sulphate proteoglycan binding promotes APRIL-induced tumour cell proliferation","volume":"12","author":"Hendriks","year":"2005","journal-title":"Cell Death Differ"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0060","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.615141","article-title":"Receptor oligomerization and its relevance for signaling by receptors of the tumor necrosis factor receptor superfamily","volume":"8","author":"Kucka","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.12.004_bib0061","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.gene.2012.02.003","article-title":"Molecular structure, expression analysis and functional characterization of APRIL (TNFSF13) gene in bat (Vespertilio superans Thomas)","volume":"498","author":"You","year":"2012","journal-title":"Gene"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0062","unstructured":"UniProt Consortium. UniProtKB \u2013 O75888 (APRIL; TNFSF13) [Homo sapiens]. Geneva (Switzerland): UniProt; [Accessed 7.11.25]. https:\/\/www.uniprot.org\/uniprotkb\/O75888\/entry."},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0063","unstructured":"National Center for Biotechnology Information (NCBI). TNFSF13 (TNF superfamily member 13), Gene ID: 8741 [Homo sapiens]. Bethesda (MD): National Library of Medicine (US); [Accessed 7.11.25]: https:\/\/www.ncbi.nlm.nih.gov\/gene\/8741."},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0064","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cytogfr.2021.08.001","article-title":"Role of the APRIL molecule in solid tumors","volume":"61","author":"Nowacka","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.12.004_bib0065","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ni1262","article-title":"The initiation of antigen-induced B cell antigen receptor signaling viewed in living cells by fluorescence resonance energy transfer","volume":"6","author":"Tolar","year":"2005","journal-title":"Nat Immunol"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.12.004_bib0066","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1111\/febs.12180","article-title":"Heparan sulphate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma","volume":"280","author":"Reijmers","year":"2013","journal-title":"FEBS J"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.12.004_bib0067","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1006\/jmbi.2001.5296","article-title":"Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes","volume":"315","author":"Karpusas","year":"2002","journal-title":"J Mol Biol"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0068","unstructured":"National Center for Biotechnology Information. TNFSF13B (tumor necrosis factor ligand superfamily member 13B) [Internet]. Gene ID: 10673 [Homo sapiens]; [Accessed 7.11.25]: https:\/\/www.ncbi.nlm.nih.gov\/gene\/10673\/."},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0069","unstructured":"Ensembl. ENSG00000102524 gene summary. [Accessed 7.11.25]: https:\/\/www.ensembl.org\/Homo_sapiens\/Gene\/Summary?g=ENSG00000102524;r=13:108251240-108308484."},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF AND APRIL: a tutorial on B cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.004_bib0071","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"31","key":"10.1053\/j.seminhematol.2025.12.004_bib0072","doi-asserted-by":"crossref","first-page":"13812","DOI":"10.1073\/pnas.1004185107","article-title":"Leptin signaling maintains B-cell homeostasis via induction of bcl-2 and cyclin D1","volume":"107","author":"Lam","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0073","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.985363","article-title":"The role of BCL-2 family proteins in regulating apoptosis and cancer therapy","volume":"12","author":"Qian","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0074","article-title":"Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Abebe","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.12.004_bib0075","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.12.004_bib0076","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.12.004_bib0077","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.clml.2022.04.025","article-title":"Matching-adjusted indirect treatment comparison of ciltacabtagene autoleucel versus other therapies in relapsed or refractory multiple myeloma (triple-class exposed patients)","volume":"22","author":"Weisel","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2025.12.004_bib0078","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study","volume":"136","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0079","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1512494","article-title":"Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products","volume":"16","author":"Alfar","year":"2025","journal-title":"Front Immunol"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0080","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.004_bib0081","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5603\/ahp.104091","article-title":"Bispecific antibodies in multiple myeloma","volume":"56","author":"Bieli\u0144ski","year":"2025","journal-title":"Acta Haematol Pol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.004_bib0082","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10059-010-0002-6","article-title":"Identification of single nucleotide polymorphisms in the TNFRSF17 gene and their association with gastrointestinal disorders","volume":"29","author":"Chae","year":"2010","journal-title":"Mol Cells"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0083","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2172-9-3","article-title":"Screening of functional and positional candidate genes in families with common variable immunodeficiency","volume":"9","author":"Salzer","year":"2008","journal-title":"BMC Immunol"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0084","unstructured":"Kalled SL, Hsu YM, Genentech Inc. Anti-BCMA antibodies and methods of use. International patent WO2010104949. 2010 ."},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.004_bib0085","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41392-023-01686-z","article-title":"Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0086","unstructured":"Fan X, Chou CC, Zhuang Q, et al.; Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors based on single-domain antibodies and methods of use thereof. International patent WO2017025038A1. World Intellectual Property Organization (WIPO); Geneva, Switzerland. 2017."},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0087","unstructured":"World Health Organization. International Nonproprietary Names (INN) for pharmaceutical substances: proposed INN: list 82. Accessed 09.12.02. https:\/\/www.who.int\/publications\/m\/item\/inn-pl-82."},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0088","unstructured":"World Health Organization. International Nonproprietary Names (INN) for pharmaceutical substances: recommended INN: list 87. Accessed 03.04.22. https:\/\/www.who.int\/publications\/m\/item\/inn-rl-87."},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0089","unstructured":"World Health Organization. International Nonproprietary Names (INN) for pharmaceutical substances: recommended INN: list 88. Accessed 11.10.22. https:\/\/www.who.int\/publications\/m\/item\/inn-rl-88."},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.12.004_bib0090","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1200\/JCO.2024.42.16_suppl.7546","article-title":"Characterization of the BCMA epitope bound by BCMA-CD3 T-cell engager elranatamab","volume":"42","author":"Josic","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2025.12.004_bib0091","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1182\/blood-2024-208776","article-title":"Characterization of linvoseltamab's BCMA binding epitope and efficacy against BCMA mutations in relapsed\/refractory multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0092","unstructured":"World Health Organization. International Nonproprietary Names (INN) for pharmaceutical substances: recommended INN: list 80. Accessed 09.09.18: https:\/\/www.who.int\/publications\/m\/item\/inn-rl-80."},{"issue":"20","key":"10.1053\/j.seminhematol.2025.12.004_bib0093","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2025.12.004_bib0094","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1177\/0961203314543914","article-title":"APRIL levels strongly correlate with IL-17 in systemic lupus erythematosus","volume":"23","author":"Eilertsen","year":"2014","journal-title":"Lupus"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.004_bib0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.20032000","article-title":"TACI and BAFF-R mediate isotype switching in B cells","volume":"201","author":"Castigli","year":"2005","journal-title":"J Exp Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.004_bib0096","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1038\/s41598-020-63390-0","article-title":"Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients","volume":"10","author":"Salazar-Camarena","year":"2020","journal-title":"Sci Rep"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.12.004_bib0097","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910845","article-title":"B-cell maturation antigen (BCMA) as a biomarker and potential treatment target in systemic Lupus erythematosus","volume":"25","author":"Martin","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0098","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1186\/ar2076","article-title":"Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"8","author":"Vallerskog","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.12.004_bib0099","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10875-005-4091-5","article-title":"Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sj\u00f6gren's syndrome","volume":"25","author":"Jonsson","year":"2005","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.12.004_bib0100","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in Systemic Lupus Erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.12.004_bib0101","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.3892\/ol.2017.6528","article-title":"Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance","volume":"14","author":"Pan","year":"2017","journal-title":"Oncol Lett"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.12.004_bib0102","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.leukres.2013.05.014","article-title":"Evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features","volume":"37","author":"Lemancewicz","year":"2013","journal-title":"Leuk Res"},{"issue":"25","key":"10.1053\/j.seminhematol.2025.12.004_bib0103","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.2024026212","article-title":"Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.12.004_bib0104","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s11523-025-01168-y","article-title":"Population exposure\u2013response efficacy analysis of elranatamab (PF-06863135) in patients with multiple myeloma","volume":"20","author":"Lon","year":"2025","journal-title":"Target Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.12.004_bib0105","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1038\/s41375-025-02757-6","article-title":"Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma","volume":"39","author":"Neubert","year":"2025","journal-title":"Leukemia"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.12.004_bib0106","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood.2024024965","article-title":"Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes","volume":"145","author":"Freeman","year":"2025","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2025.12.004_bib0107","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood-2024-204524","article-title":"Steric hindrance by APRIL in binding of BCMA-directed bispecific antibodies: a novel refractory mechanism of BCMA-directed immunotherapies in multiple myeloma","volume":"144","author":"Harada","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.12.004_bib0108","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.12.004_bib0109","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv."},{"issue":"21","key":"10.1053\/j.seminhematol.2025.12.004_bib0110","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1182\/bloodadvances.2023010025","article-title":"Monoallelic deletion of BCMA is a frequent feature in multiple myeloma","volume":"7","author":"Samur","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.004_bib0111","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.12.004_bib0112","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/cancers10090323","article-title":"CAR-T cells based on novel BCMA monoclonal antibody block multiple myeloma cell growth","volume":"10","author":"Berahovich","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2025.12.004_bib0113","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2023-180013","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-cell maturation antigen\u202f\u00d7\u202fCD3 T-cell engager administered subcutaneously in patients with relapsed\/refractory multiple myeloma: updated results from a phase 1 first-in-human clinical study","volume":"142","author":"Bar","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0114","unstructured":"Created with BioRender.com. BioRender; [Accessed 7.11.25]. https:\/\/www.biorender.com."},{"issue":"20","key":"10.1053\/j.seminhematol.2025.12.004_bib0115","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1093\/bioinformatics\/btv362","article-title":"IBS: an illustrator for the presentation and visualization of biological sequences","volume":"31","author":"Liu","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0116","doi-asserted-by":"crossref","unstructured":"Hymowitz SG, Patel DR, Wallweber HJA, et al. The crystal structure of APRIL bound to BCMA. RCSB protein Data Bank. 2004. DOI: 10.2210\/pdb1XU2\/pdb.","DOI":"10.2210\/pdb1xu1\/pdb"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0117","doi-asserted-by":"crossref","unstructured":"Hymowitz SG, Patel DR, Wallweber HJA, et al. Crystal structure of the BAFF-BAFF-R complex. RCSB protein Data Bank. 2003. DOI: 10.2210\/pdb4V46\/pdb.","DOI":"10.2210\/pdb4v46\/pdb"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0118","doi-asserted-by":"crossref","unstructured":"Hymowitz SG, Patel DR, Wallweber HJA, et al. Pentagonal cluster of BAFF-BAFFR ectodomain complex. RCSB Protein Data Bank. 2025. DOI: 10.2210\/pdb8ZUJ\/pdb.","DOI":"10.2210\/pdb8zuj\/pdb"},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0119","unstructured":"UniProt Consortium. Tumor necrosis factor ligand superfamily member 13B (TNFSF13B) \u2013 Homo sapiens. UniProtKB; [Accessed 7.11.25]. https:\/\/www.uniprot.org\/uniprotkb\/Q9Y275\/entry."},{"key":"10.1053\/j.seminhematol.2025.12.004_bib0120","unstructured":"Schr\u00f6dinger L, DeLano W. PyMOL [Internet]. 2020. Available from: http:\/\/www.pymol.org\/pymol."},{"issue":"4","key":"10.1053\/j.seminhematol.2025.12.004_bib0121","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/bib\/bbx108","article-title":"MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization","volume":"20","author":"Katoh","year":"2019","journal-title":"Brief Bioinform"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:01:52Z","timestamp":1778724112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":121,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0037196325000587"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.12.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}